Enterprise Value
42.57M
Cash
152.5M
Avg Qtr Burn
-5.869M
Short % of Float
0.13%
Insider Ownership
5.83%
Institutional Own.
74.74%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Masofaniten (EPI-7386) (antiandrogen) combo w/ enzalutamide Details Prostate cancer, Cancer | Phase 1/2 Data readout | |
EPI-7386 (antiandrogen) Monotherapy Details Castration-resistant prostate cancer | Phase 1b Update | |
EPI-7386 (antiandrogen) comb w/ apalutamide and abiraterone acetate Details Cancer, Prostate cancer | Phase 1 Initiation |